News and Views
Nature Genetics 39, 1057 - 1059 (2007)
doi:10.1038/ng0907-1057
Cancer drugs to treat birth defects
Andrew O M Wilkie1
- Andrew O.M. Wilkie is at the Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK. e-mail: awilkie@hammer.imm.ox.ac.uk
Abstract
Identical mutations of the same genes can lead either to congenital malformations or to cancer, depending on their cellular and temporal context. The demonstration of activated RAS-ERK signaling in a mouse model of Apert syndrome suggests that drugs designed to inhibit this pathway in cancer may also delay the progression of several serious pediatric syndromes.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Research HighlightsNature Medicine News and Views (01 Oct 2007)
Craniofacial syndromes: no such thing as a single gene diseaseNature Genetics News and Views (01 Feb 1995)
RESEARCH
RNA interference and inhibition of MEK - ERK signaling prevent abnormal skeletal phenotypes in a mouse model of craniosynostosisNature Genetics Letter (01 Sep 2007)
Identical mutations in three different fibroblast growth factor receptor genes in autosomal dominant craniosynostosis syndromesNature Genetics Letter (01 Oct 1996)
See all 10 matches for Research